Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants
21 juni 2026 uppdaterad av: International Vaccine Institute
A Phase 1/2a, Randomized, Observer-blind, Age-descending, Dose Finding Study to Evaluate the Safety and Immunogenicity of Institut Pasteur Quadrivalent Shigella Vaccine (IP-QSV) for Intramuscular Administration in Healthy Adults/Adolescents, Children and Infants
The goal of this phase 1/2a, randomized, observer-blind, age-descending, dose-finding trial is to evaluate the safety and immunogenicity of a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV) in adults, children, and infants in Mali.
This first-in-human study is intended to obtain initial data on the safety of the adjuvanted IP-QSV vaccine and its effect on immune responses in a Shigella-endemic region.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Detaljerad beskrivning
this is phase 1/2a, randomized, observer-blind, age-descending, dose-finding trial to evaluate the safety and immunogenicity of a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV) in adults, children, and infants in Mali
A total of 370 healthy participants aged 6 months to 45 years in Mali will be enrolled and randomly assigned in a 2:1 or 2:2:1 ratio. The study groups are as follow
- Group A (18-45 years): one dose of 30 µg IP / placebo in a 2:1 ratio
- Group B (2-5 years): two doses of 10 µg IP / placebo administered 3 months apart in a 2:1 ratio
- Group C (2-5 years): one dose of 30 µg IP / placebo in a 2:1 ratio
- Group D (6-8 months): three doses of 2 µg IP / placebo administered at 3- and 6-month intervals in a 2:1 ratio
- Group E (6-8 months): three doses of 10 µg IP or placebo administered at 3- and 6-month intervals in a 2:2:1 ratio
- Group F (9-11 months): two doses of 10 µg IP / placebo administered 6 months apart in a 2:1 ratio
- Group G (6-8 months): two doses of 30 µg IP or placebo administered 9 months apart in a 2:1 ratio.
The DSMB must review the safety data of each group and approve study continuation before investigational product administration of the next group is initiated.
Participants will attend between 5 and 11 scheduled study visits, including blood sampling for immunogenicity assessments and safety evaluations. Blood samples will be collected at screening and at multiple time points throughout the study to assess immune responses and overall health status. Baseline laboratory assessments will include HIV testing, hepatitis screening, complete blood counts, and renal and liver function tests. Women of childbearing potential will undergo pregnancy testing at screening.
Serious adverse events (SAEs) will be reported and followed until resolution or stabilization. Participants will be instructed to contact the study team immediately if they experience any serious adverse event.
The study will monitor for SAEs, including hospitalization, death, or significant disability, occurring during the study, regardless of whether they are considered related to the study vaccine. Immediate reactions occurring within 0.5 - 1 hours after vaccination will be monitored to detect allergic or other acute responses. Solicited mild to moderate adverse events, such as nausea, fever, and diarrhea, will be recorded for up to 7 days after each vaccination.
Studietyp
Interventionell
Inskrivning (Beräknad)
370
Fas
- Fas 2
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Tarun Saluja, MD
- Telefonnummer: +82 2 8811 236
- E-post: tarun.saluja@ivi.int
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Individuals aged 18-45 years in Group A, 2-5 years in Groups B and C, 6-8 months in Groups D, E and G , and 9-11 months in Group F
- Participants/ Participants' Legally Acceptable representative (LAR) willing to provide written informed consent to participate in the study voluntarily
- Participants who can comply with the study requirements
- Individuals in good health as determined by the outcome of medical history, physical examination, and the clinical judgment of the investigator
Exclusion Criteria:
- Known history or allergy to investigational vaccine components or other medications, or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial
- Individuals with major congenital abnormalities, developmental disorders, genetic defects, or severe malnutrition, among other conditions which in the opinion of investigator may affect the participant's participation in the study
- Known history of immune function disorders including immunodeficiency diseases (known HIV infection¥ or other immune function disorders) which in the opinion of investigator may affect the participant's participation in the study or interfere with the assessment of the study objectives
- Use of systemic steroids within past 6 months (>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months
- Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives
- Individuals with behavioral or cognitive impairment or psychiatric disease or neural disorders that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial
- Individuals with splenectomy
- Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time resulting in contraindication for IM injections/blood extractions
- Receipt of blood, blood-derived products, or immunoglobulin products in the past 3 months
- Individuals who have received other vaccines from 4 weeks prior to the first dose of investigational product administration or planned to receive any vaccine within 4 weeks post any dose of the investigational product
- Individuals with active or known previous culture-proven Shigella infection
- Individuals who have household contact with/and /or intimate exposure to an individual with laboratory confirmed Shigella infection
- Previous participation in any study in which a Shigella-vaccine candidate was administered
- Individuals with a history of severe diarrhea in the last 6 months requiring care at a medical facility lasting 24 hours or more
- Individuals with a history of clinically significant gastrointestinal disorders or with any history of frequent diarrhea, nausea or emesis, within the last 6 months
- Individuals aged below 5 years with Weight for Height Z score and/or Height for Age Z score of less than -3
- Any female participant who is lactating or pregnant#
- Females of childbearing potential who do not agree to use an effective birth control method* for at least 4 weeks before the screening and up to 12 weeks after the investigational product administration
- Individuals enrolled in another clinical trial within 6 months prior to enrollment, concomitantly enrolled or scheduled to be enrolled in another trial during study period
- Individuals who are research staff involved with the clinical trial or household members of research staff
- As per Investigator's medical judgement, an individual could be excluded from the study despite meeting all inclusion/exclusion criteria mentioned above
- Special Conditions for Children Aged 24 Months and Below: For such children, additional exclusion criteria include difficult birth, resuscitation after suffocation, a history of neurological damage, premature birth (delivery before the 37th week of gestation), and low birth weight (less than 2500 grams)
- Clinically significant abnormal findings in blood tests during the screening
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group A
A total of 30 participants aged 18-45 years will receive one dose of 30 µg IP-QSV or placebo.
|
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.
|
|
Experimentell: Group B
A total of 30 participants aged 2-5 years will receive two doses of 10 µg IP-QSV or placebo at 3 months interval.
|
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
|
|
Experimentell: Group C
A total of 30 participants aged 2-5 years will receive one dose of 30 µg IP-QSV or placebo
|
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.
|
|
Placebo-jämförare: Group D
A total of 60 participants aged 6-8 months will receive three doses of 2 µg IP-QSV or placebo at Months 0, 3, and 9.
|
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
|
|
Experimentell: Group E
A total of 100 participants aged 6-8 months will receive three doses of 10 µg IP-QSV or placebo at Months 0, 3, and 9.
|
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
|
|
Experimentell: Group F
A total of 60 participants aged 9-11 months will receive two doses of 10 µg IP-QSV or placebo at 6 months interval
|
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
|
|
Experimentell: Group G
A total of 60 participants aged 6-8 months will receive two doses of 30 µg IP-QSV or placebo at 9 months interval
|
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein.
30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Efterfrågade biverkningar
Tidsram: Inom 7 dagar efter varje dos
|
Förekomst av efterfrågat injektionsställe och begärda systemiska biverkningar från tidpunkten för varje studievaccination till 7 dagar efter varje studievaccination
|
Inom 7 dagar efter varje dos
|
|
Oönskade biverkningar
Tidsram: Inom 28 dagar efter varje dos
|
Förekomst av oönskade biverkningar från tidpunkten för varje studievaccination till 28 dagar efter varje studievaccination.
|
Inom 28 dagar efter varje dos
|
|
Allvarliga biverkningar (SAE) och biverkningar av särskilt intresse (AESI) samt medicinskt behandlade biverkningar (MAAE)
Tidsram: genom studiens genomförande, i genomsnitt 6 månader
|
Förekomst av någon SAE / AESI / MAAE från första dosvaccinering genom hela slutbesöket i studien
|
genom studiens genomförande, i genomsnitt 6 månader
|
|
Omedelbara biverkningar
Tidsram: Inom 30 minuter efter varje dos
|
Förekomst av omedelbara biverkningar inom 30 minuter efter varje vaccindos
|
Inom 30 minuter efter varje dos
|
|
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post primary IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Tidsram: Baseline, at 4 weeks, and at 6 months post primary IP administration series
|
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs (for each one of the four serotypes and combined serotypes (SF all)), after 2-dose primary series (0-3-month) of 2μg of IP-QSV / placebo, or 2-dose primary series (0-3-month) of 10μg of IP-QSV / placebo, or Single primary dose of 30μg of IP-QSV / placebo
|
Baseline, at 4 weeks, and at 6 months post primary IP administration series
|
|
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post primary IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Tidsram: at 4 weeks and at 6 months post primary IP administration series
|
Percentage of seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes and combined serotypes (SF2a, SF3a, SF6, Sson LPSs, SF all), after 2-dose primary series (0-3-month) of 2μg of IP-QSV / placebo or 2-dose primary series (0-3-month) of 10μg of IP-QSV / placebo or Single primary dose of 30μg of IP-QSV / placebo
|
at 4 weeks and at 6 months post primary IP administration series
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Tidsram: Baseline, at 4 weeks, and at 6 months post full IP administration series
|
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs, (for each one of the four serotypes and combined serotypes (SF all)), after 3 doses(0-3-9-month) of 2μg IP-QSV / placebo, or 3 doses ( 0-3-9-month) of 10μg IP-QSV / placebo, or 2 doses ( 0-9-month) of 30μg IP-QSV / placebo
|
Baseline, at 4 weeks, and at 6 months post full IP administration series
|
|
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Tidsram: Baseline, at 4 weeks, and at 6 months post full IP administration series
|
Percentage of seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes (SF2a, SF3a, SF6 & Sson LPSs, and combined serotypes (SF, all)), after 3 doses ( 0-3-9-month) of 2μg IP-QSV / placebo, or 3 doses ( 0-3-9-month)of 10μg IP-QSV / placebo, or 2 doses ( 0-9-month) of 30μg IP-QSV / placebo
|
Baseline, at 4 weeks, and at 6 months post full IP administration series
|
|
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series and at 6 months post full IP administration of IP-QSV 10μg OS-equivalent dosages in infants aged 9-11 month
Tidsram: Baseline and at post each dose of full IP administration series
|
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs(for each one of the four serotypes and combined serotypes (SF, all)), at 4 weeks after 1 and 2 doses ( 0-6-month) of 10μg of IP-QSV / placebo
|
Baseline and at post each dose of full IP administration series
|
|
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series and at 6 months post full IP administration of IP-QSV 10μg OS-equivalent dosages in infants aged 9-11 months
Tidsram: at post each dose of full IP administration series
|
Percentage of Seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes (SF2a, SF3a, SF6 & Sson LPSs, and combined serotypes (SF, all)) at 4 weeks after 1 and 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo
|
at post each dose of full IP administration series
|
|
GMT of SF2a, SF3a, SF6 & Sson -specific serum bactericidal antibodies (SBA) at 4 weeks and at 6 months post primary IP and full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-11 months
Tidsram: Baseline, at 4 weeks and at 6 months post primary and full IP administration series
|
GMT of SBA to SF2a, SF3a, SF6 & Sson, independently for each one of the four serotypes and combined serotypes (SF, all), after 2-dose primary series (0-3-month) of 2/10μg of IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 30μg of IP-QSV / placebo in infants aged 6-8 months, or 3 doses in 0-3-9-month dose schedule of 2/10μg IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 10μg of IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-9-month dose schedule of 30μg IP-QSV / placebo in infants aged 6-8 months
|
Baseline, at 4 weeks and at 6 months post primary and full IP administration series
|
|
Seroconversion of SF2a, SF3a, SF6 & Sson -specific serum bactericidal antibodies (SBA) at 4 weeks and at 6 months post primary IP and full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-11 months
Tidsram: at 4 weeks and at 6 months post primary and full IP administration series
|
Percentage of seroconversion of SBA to SF2a, SF3a, SF6 & Sson, independently for each one of the four serotypes and combined serotypes (SF, all), after 2-dose primary series (0-3-month) of 2/10μg of IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 30μg of IP-QSV / placebo in infants aged 6-8 months, or 3 doses in 0-3-9-month dose schedule of 2/10μg IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 10μg of IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-9-month dose schedule of 30μg IP-QSV / placebo in infants aged 6-8 months
|
at 4 weeks and at 6 months post primary and full IP administration series
|
|
GMT of serum IgG against SF2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series of IP-QSV 10/30μg OS-equivalent dosages in adults aged 18-45 years and children aged 2-5 years
Tidsram: Baseline and at 4 weeks post each dose of full IP administration series
|
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson, and percentage of seroconversion, after 1 dose of 30μg in adults aged 18-45 years and in children aged 2-5 years or after each dose of 10μg in 0-3mo dose schedule in children aged 2-5 years
|
Baseline and at 4 weeks post each dose of full IP administration series
|
|
Seroconversion of serum IgG against SF2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration of IP-QSV 10/30μg OS-equivalent dosages in adults aged 18-45 years and children aged 2-5 years
Tidsram: at 4 weeks post each dose of full IP administration series
|
Percentage of seroconversion of serum IgG antibodies to SF2a, SF3a, SF6 & Sson, after 1 dose of 30μg in adults aged 18-45 years and in children aged 2-5 years or after each dose of 10μg in 0-3mo dose schedule in children aged 2-5 years
|
at 4 weeks post each dose of full IP administration series
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Samba Sow, MD, CVD-Mali
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 juli 2026
Primärt slutförande (Beräknad)
1 augusti 2027
Avslutad studie (Beräknad)
1 november 2028
Studieregistreringsdatum
Först inskickad
6 december 2025
Först inskickad som uppfyllde QC-kriterierna
21 juni 2026
Första postat (Faktisk)
24 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
21 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IVI IP QSV
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .